Why the study?
Noninvasive methods are needed to replace liver biopsy for identifying nonalcoholic steatohepatitis and fibrosis in children with nonalcoholic fatty liver disease.
Can noninvasive diagnostic tools accurately diagnose NASH and advanced fibrosis in pediatric patients with NAFLD?
Can noninvasive diagnostic tools accurately diagnose NASH and advanced fibrosis in pediatric patients with NAFLD?
Noninvasive diagnostic tools for pediatric NAFLD currently cannot replace liver biopsy for diagnosing NASH or fibrosis degree, but may be useful for monitoring disease progression.
Noninvasive tests should not replace biopsy for NASH diagnosis in pediatric NAFLD; leaves open complementary monitoring role pending prospective validation.
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease in the pediatric population. It is a significant liver complication of obesity that also prominently affects children. Over the past decade, several noninvasive methods have been investigated for replacing liver biopsy to identify which children with NAFLD have nonalcoholic steatohepatitis (NASH) and fibrosis. These methods that aim to differentiate the type and extent of liver damage are based on two main different methodologies: a 'biological' approach centered on the quantification of circulating biomarkers; and a 'physical' approach established by analyzing different imaging data. AREAS COVERED: In this review, we illustrate the state of the art and recent discoveries on noninvasive methods for the diagnosis of NAFLD, NASH, and advanced fibrosis. EXPERT OPINION: Currently, noninvasive tests cannot diagnose NASH or determine the degree of fibrosis. However, several lines of evidence have suggested that if these tests are used in a complementary way with other laboratory tests and imaging they have the potential to be used to monitor progression of disease and response to therapy in pediatric NAFLD. Future scientific research will focus on combining these methods with multiple potential predictors of genetic susceptibility.
No takes yet. Share an insight, caveat, or question.
Mosca et al. (2020) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: